Lombard Odier Asset Management (Switzerland)’s Neurocrine Biosciences NBIX Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-133,656	Closed	-$13.5M	–	302
2023 Q1	$13.5M	Sell	133,656 -3,794	-3%	-$395K	1.18%	28
2022 Q4	$16.4M	Sell	137,450 -61,642	-31%	-$7.22M	1.31%	26
2022 Q3	$21.1M	Sell	199,092 -15,838	-7%	-$1.61M	1.79%	10
2022 Q2	$21M	Buy	214,930 +24,362	+13%	+$2.25M	1.77%	12
2022 Q1	$17.9M	Sell	190,568 -72,097	-27%	-$6.11M	1.4%	33
2021 Q4	$22.4M	Buy	262,665 +22,682	+9%	+$2.09M	1.43%	28
2021 Q3	$23M	Buy	239,983 +23,192	+11%	+$2.19M	1.43%	32
2021 Q2	$21.1M	Buy	216,791 +66,927	+45%	+$6.41M	1.07%	40
2021 Q1	$14.6M	Buy	+149,864	New	+$15.7M	0.97%	42

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s NBIX Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 133,656 shares — an estimated $13.5M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in NBIX in Q1 2021 and held it in 9 quarters. The position peaked at $23M in Q3 2021. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 133,656 Neurocrine Biosciences shares in Q2 2023, an estimated $13.5M.
Lombard Odier Asset Management (Switzerland) first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 9 quarters.
Lombard Odier Asset Management (Switzerland)'s Neurocrine Biosciences position peaked at $23M in Q3 2021.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.